Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Improved first progression-free survival following allogeneic hematopoietic cell transplantation relapse with the use of immunotherapy.

Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post-HCT, but published clinical experience is primarily with the first-generation TKI imatinib while data with newer generation TKIs are limited. We conducted a retrospective analysis of 185 Ph+ ALL patients who underwent HCT followed by TKI maintenance from 2003 to 2021 at City of Hope. Initially, 50 (27.0%) received imatinib, 118 (63.8%) received a second-generation TKI (2G-TKI), and 17 (9.2%) received ponatinib. A total of 77 patients (41.6%) required a dose reduction of their initial TKI due to toxicity. Sixty-six patients (35.7%) did not complete maintenance due to toxicity; 69 patients (37.3%) discontinued 1 TKI, and 11 (5.9%) discontinued 2 TKIs due to toxicity. Initial imatinib versus 2G-TKI versus ponatinib maintenance was discontinued in 19 (38.0%) versus 68 (57.6%) versus 3 (17.6%) patients due to toxicity (p = .003), respectively. Patients on ponatinib as their initial TKI had a longer duration of TKI maintenance versus 2G-TKI: 576.0 days (range, 72-921) versus 254.5 days (range, 3-2740; p = .02). The most common reasons for initial TKI discontinuation include gastrointestinal (GI) intolerance (15.1%), cytopenia (8.6%), and fluid retention (3.8%). The 5-year overall survival and progression-free survival for the total population were 78% and 71%, respectively. Our findings demonstrate the challenges of delivering post-HCT TKI maintenance in a large real-world cohort as toxicities leading to TKI interruptions, discontinuation, and dose reduction were common.

Patterns of interventions for central venous catheter-associated deep vein thrombosis and outcomes in cancer patients.

PURPOSE: This letter evaluated the impact of different management strategies, specifically the presence or absence of therapeutic anticoagulation, on clinical outcomes for central venous catheter (CVC)-associated deep vein thrombosis (DVT) in cancer patients. METHODS: One-hundred ninety-eight adult cancer patients with a confirmed CVC-associated DVT diagnosis from February 2013 and February 2021 were included. RESULTS: Incidence of symptomatic recurrent venous thromboembolism (VTE) was similar between patients who received therapeutic anticoagulation and those who did not (14% vs 16%, p = 0.807). In addition, therapeutic anticoagulation did not significantly alter the incidence of grade 3 and above bleeding events despite most patients having hematologic malignancies (9% vs 8%, p = 0.826). CONCLUSION AND RELEVANCE: Therapeutic anticoagulation was not associated with a reduction in the incidence of recurrent VTE or increase the incidence of bleeding in adult cancer patients following a CVC-associated DVT diagnosis.

The interplay of membrane fluidity, acyl chain order and area per lipid on the partitioning of two antidepressants paroxetine and sertraline.

Selective serotonin reuptake inhibitors (SSRIs) are among the popular drugs for treating depression and mental disorders. Membrane fluidity has previously been considered as the main factor in modulating the membrane partitioning of SSRIs, while other biophysical properties, such as the acyl chain order and area per lipid, were often neglected. Varying the lipid membrane composition and temperature can significantly modify the physical phase and, in turn, affect its fluidity, acyl chain order and area per lipid. Here, we investigate the role of membrane fluidity, acyl chain order and area per lipid in the partitioning of two SSRIs, paroxetine (PAX) and sertraline (SER). The model membranes were either POPC : SM (1 : 1 mol ratio) or POPC : SM : Chol (1 : 1 : 1 mol ratio) and studied in the temperature range of 25-45 °C. The order parameters and area per lipid in the two lipid mixtures were calculated using molecular dynamics simulations. The membrane partitioning of PAX and SER was determined via second derivative spectrophotometry. In a lower temperature range (25-32 °C), membrane fluidity favors the SSRI partitioning into Lo/Ld POPC:SM:Chol. In a higher temperature range (37-45 °C), the interplay between membrane fluidity, acyl chain order and area per lipid favors drug partitioning into Ld POPC:SM. The findings offer indication for the inconsistent distribution of SSRIs in tissues as well as the possible interaction of SSRIs with lipid domains and membrane-bound proteins.

Cladribine, Cytarabine, and Etoposide-Based Regimens Are Safe and Tolerable In Relapsed and Refractory Acute Myeloid Leukemia Patients.

Intensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analog. In patients who cannot tolerate an anthracycline due to comorbidities, one may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogs, such as cladribine, in combination with cytarabine and etoposide in patients who may be eligible for intensive chemotherapy but not able to tolerate an anthracycline due to comorbidities or cardiotoxicity risks. Here, we present 4 patients who received a cladribine, cytarabine, and etoposide (CCE) based regimen for R/R AML. There were no significant therapy-related adverse events, dose holds, or delays. Two out of 3 evaluable patients were successfully bridged to allogeneic transplant, and one is pending another cycle of chemotherapy as a bridge to transplant. The CCE regimen offers a potential option for patients with R/R AML in need of an anthracycline-free salvage regimen during a fludarabine shortage.

Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience.

Patients living with HIV are now living longer due to increased access to antiretroviral therapy (ART) and a decrease in acquired immunodeficiency syndrome-defining cancer (ADC). However, increasing age and previous chemotherapy exposure for ADC (e.g., anthracyclines and topoisomerase inhibitors) are factors that may increase the risk of developing therapy-related myelodysplastic syndrome and acute myeloid leukemia (AML) and highlight an unmet need. There are no established guidelines for the treatment of AML in patients with HIV and the literature is limited to treatment outcomes and experience. In addition, cladribine, a purine analog used in AML, has a package insert warning to avoid administration with concurrent agents that undergo phosphorylation, which include HIV ART backbones (e.g., nucleoside reverse transcriptase inhibitors [NRTI]). Whether concurrent NRTI-based ART is deliverable with AML induction chemotherapy has not been reported previously. In our single-center experience of seven HIV-AML patients, all patients continued concurrent ART with induction chemotherapy. In 6 evaluable patients, three (50%) of patients went into complete remission (CR). Five (71.4%) patients were able to proceed to allogenic hematopoietic stem cell transplantation (HCT). Median OS was 16.6 months, with patients who received HCT having longer median OS compared to those who were unable to proceed to HCT (49.6 months vs. 3.4 months). Interestingly, none of the patients who received AML regimens that included fludarabine were able to obtain a response. On the contrary, 4 patients who received AML regimens that utilized cytarabine given over a prolonged period of time (e.g., 7 + 3, liposomal daunorubicin/cytarabine) achieved a CR rate of 75%. Concurrent HIV ART and AML induction chemotherapy is deliverable, although much remains to be investigated on potential drug interactions between purine analog-based chemotherapy and HIV ART.

A Multicenter Study of Clinicopathology and Immunohistochemical Distinction between Adult and Pediatric Large B-Cell Lymphoma.

Introduction: Pediatric DLBCL is considered a homogenous group and has superior outcomes compared to adults. This study investigated the clinical pathology and immunohistochemical distinction between adult and pediatric large B-cell lymphoma. Methods: A cross-sectional study of 314 NHLs with the morphology of diffuse pattern, large B-cell, and CD20 expression was investigated. Results: Of 314 cases, there were 6 cases of pleomorphic MCL (all in adults), 19 cases of Burkitt lymphoma (all in children), and 289 cases of DLBCL. Pediatric DLBCL had many striking differences: More frequency in extra-nodal sites; a higher proportion of centroblastic morphology; a predominance of GCB-type; a high proliferation rate; an infrequency of Bcl2 protein expression, and a lack of double-expresser lymphoma. Conclusions: Our study demonstrated the significant biological differences between adult and pediatric DLBCL.

Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.

BACKGROUND: Blinatumomab has demonstrated encouraging activity in relapsed/refractory (r/r) and minimal residual disease-positive (MRD+) acute lymphoblastic leukemia (ALL). Extramedullary disease (EMD) relapse or relapse with CD19- disease has been observed after blinatumomab therapy in patients with r/r or MRD+ ALL. However, the pathophysiology and risk factors of treatment failure are not fully understood. METHODS: This study retrospectively reviewed the outcomes of adult patients with B-cell ALL treated with blinatumomab (n = 132) for either r/r (n = 103) or MRD+ disease (n = 29) at the authors' center (2013-2021) and analyzed factors associated with treatment response and EMD failure. RESULTS: The overall response rate was 64%. A lower marrow blast burden before blinatumomab (P = .049) and no history of previous EMD (P = .019) were significantly associated with a higher response. Among the patients who responded to blinatumomab, 56% underwent consolidation with allogeneic transplantation. Blinatumomab failure was observed in 89 patients; 43% of these patients (n = 38) either progressed or relapsed at extramedullary sites. A history of extramedullary involvement (53% vs 24%; P = .005) and retention of CD19 expression at the time of relapse/progression (97% vs 74%; P = .012) were associated with a higher risk for extramedullary failure. Central nervous system (CNS) failure after blinatumomab was encountered in 39% of the patients with EMD. CONCLUSIONS: A history of EMD predicted an inferior response to blinatumomab therapy with a higher risk for relapse/progression at extramedullary sites (particularly CNS). Consolidation with allogenic transplantation in patients who primarily responded to blinatumomab did not abrogate the risk of extramedullary relapse. The incorporation of extramedullary assessment and the intensification of CNS prophylaxis may help in addressing extramedullary failure. LAY SUMMARY: Extramedullary failure is common during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. A history of extramedullary disease predicts an inferior response to blinatumomab therapy and a higher risk for relapse/progression at extramedullary sites. Most extramedullary failure cases retain CD19 expression.

Adapting a Dehazing System to Haze Conditions by Piece-Wisely Linearizing a Depth Estimator.

Haze is the most frequently encountered weather condition on the road, and it accounts for a considerable number of car crashes occurring every year. Accordingly, image dehazing has garnered strong interest in recent decades. However, although various algorithms have been developed, a robust dehazing method that can operate reliably in different haze conditions is still in great demand. Therefore, this paper presents a method to adapt a dehazing system to various haze conditions. Under this approach, the proposed method discriminates haze conditions based on the haze density estimate. The discrimination result is then leveraged to form a piece-wise linear weight to modify the depth estimator. Consequently, the proposed method can effectively handle arbitrary input images regardless of their haze condition. This paper also presents a corresponding real-time hardware implementation to facilitate the integration into existing embedded systems. Finally, a comparative assessment against benchmark designs demonstrates the efficacy of the proposed dehazing method and its hardware counterpart.

A Clinical Review of Biosimilars Approved in Oncology.

OBJECTIVE: To summarize and review the clinical data of Food and Drug Administration (FDA)-approved biosimilars for use in treatment of cancer and the current challenges health care institutions face when implementing a newly approved biosimilar. DATA SOURCES: A literature search of the following databases was performed between January 1, 2012, and December 31, 2019: PubMed, Google, and ClinicalTrials.gov. Search terms included the words biosimilar, bevacizumab, rituximab, and/or trastuzumab. STUDY SELECTION AND DATA EXTRACTION: Only primary literature on biosimilars with an ongoing or completed phase 3 trial and/or FDA approval were included in the final analysis. Primary literature consisted of peer-reviewed publications, published abstracts, and any results posted on the ClinicalTrials.gov database. DATA SYNTHESIS: Clinical trials of FDA-approved biosimilars for bevacizumab, rituximab, and trastuzumab showed no significant differences with respect to efficacy, safety, and pharmacokinetics when compared with their reference products. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: The anticipated growth of biologics in oncology and the recent introduction of biosimilars over the past few years have placed a lot of emphasis on biosimilars as a significant source of cost savings for the health care system. Our article compiles and analyzes existing data on biosimilar efficacy, safety, and financial impact. CONCLUSIONS: The major concerns of biosimilars revolve around their long-term efficacy and safety. Even with many questions to be answered, biosimilars have the potential for significant cost savings in the US health care system.

Haziness Degree Evaluator: A Knowledge-Driven Approach for Haze Density Estimation.

Haze is a term that is widely used in image processing to refer to natural and human-activity-emitted aerosols. It causes light scattering and absorption, which reduce the visibility of captured images. This reduction hinders the proper operation of many photographic and computer-vision applications, such as object recognition/localization. Accordingly, haze removal, which is also known as image dehazing or defogging, is an apposite solution. However, existing dehazing algorithms unconditionally remove haze, even when haze occurs occasionally. Therefore, an approach for haze density estimation is highly demanded. This paper then proposes a model that is known as the haziness degree evaluator to predict haze density from a single image without reference to a corresponding haze-free image, an existing georeferenced digital terrain model, or training on a significant amount of data. The proposed model quantifies haze density by optimizing an objective function comprising three haze-relevant features that result from correlation and computation analysis. This objective function is formulated to maximize the image's saturation, brightness, and sharpness while minimizing the dark channel. Additionally, this study describes three applications of the proposed model in hazy/haze-free image classification, dehazing performance assessment, and single image dehazing. Extensive experiments on both real and synthetic datasets demonstrate its efficacy in these applications.

Automating a Dehazing System by Self-Calibrating on Haze Conditions.

Existing image dehazing algorithms typically rely on a two-stage procedure. The medium transmittance and lightness are estimated in the first stage, and the scene radiance is recovered in the second by applying the simplified Koschmieder model. However, this type of unconstrained dehazing is only applicable to hazy images, and leads to untoward artifacts in haze-free images. Moreover, no algorithm that can automatically detect the haze density and perform dehazing on an arbitrary image has been reported in the literature to date. Therefore, this paper presents an automated dehazing system capable of producing satisfactory results regardless of the presence of haze. In the proposed system, the input image simultaneously undergoes multiscale fusion-based dehazing and haze-density-estimating processes. A subsequent image blending step then judiciously combines the dehazed result with the original input based on the estimated haze density. Finally, tone remapping post-processes the blended result to satisfactorily restore the scene radiance quality. The self-calibration capability on haze conditions lies in using haze density estimate to jointly guide image blending and tone remapping processes. We performed extensive experiments to demonstrate the superiority of the proposed system over state-of-the-art benchmark methods.

Visibility Restoration: A Systematic Review and Meta-Analysis.

Image acquisition is a complex process that is affected by a wide variety of internal and environmental factors. Hence, visibility restoration is crucial for many high-level applications in photography and computer vision. This paper provides a systematic review and meta-analysis of visibility restoration algorithms with a focus on those that are pertinent to poor weather conditions. This paper starts with an introduction to optical image formation and then provides a comprehensive description of existing algorithms as well as a comparative evaluation. Subsequently, there is a thorough discussion on current difficulties that are worthy of a scientific effort. Moreover, this paper proposes a general framework for visibility restoration in hazy weather conditions while using haze-relevant features and maximum likelihood estimates. Finally, a discussion on the findings and future developments concludes this paper.

Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.

FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent in acute myeloid leukemia (AML), and their presence confers adverse risk. FLT3-mutated (FLT3m) AML is a challenging leukemia to manage, particularly in older and unfit patients as well as patients with relapsed/refractory (r/r) disease. We retrospectively analyzed the outcomes of 50 FLT3m AML patients (17 treatment-naïve, 33 r/r) treated with venetoclax (VEN) and hypomethylating agents (HMA). The overall CR/CRi rate with VEN-HMA was 60% (94% in treatment-naïve AML and 42% in r/r AML). Early (60-days) treatment related mortality was 2%. The r/r AML setting was an independent predictor of lower complete response (OR: 0.08; 95%CI: 0.00-0.60, P = .03). Cytogenetics-molecular risk, concurrent mutations, the type of FLT3 mutation (ITD vs TKD), the ITD allelic ratio, the type of HMA, age, prior exposure to HMA and receipt of prior allogeneic transplant did not independently impact response or leukemia-free survival (LFS). Concurrent IDH mutations were associated with lower CR/CRi (P = .01), while ASXL1 or TET2 mutations showed a non-significant association toward higher CR/CRi (P = .07, for both). However, none of the concurrent mutations were an independent predictor for response when adjusted to AML setting. In conclusion, VEN-HMA is associated with encouraging efficacy in FLT3m AML among both newly diagnosed unfit and r/r patients.

Single-Image Visibility Restoration: A Machine Learning Approach and Its 4K-Capable Hardware Accelerator.

In recent years, machine vision algorithms have played an influential role as core technologies in several practical applications, such as surveillance, autonomous driving, and object recognition/localization. However, as almost all such algorithms are applicable to clear weather conditions, their performance is severely affected by any atmospheric turbidity. Several image visibility restoration algorithms have been proposed to address this issue, and they have proven to be a highly efficient solution. This paper proposes a novel method to recover clear images from degraded ones. To this end, the proposed algorithm uses a supervised machine learning-based technique to estimate the pixel-wise extinction coefficients of the transmission medium and a novel compensation scheme to rectify the post-dehazing false enlargement of white objects. Also, a corresponding hardware accelerator implemented on a Field Programmable Gate Array chip is in order for facilitating real-time processing, a critical requirement of practical camera-based systems. Experimental results on both synthetic and real image datasets verified the proposed method's superiority over existing benchmark approaches. Furthermore, the hardware synthesis results revealed that the accelerator exhibits a processing rate of nearly 271.67 Mpixel/s, enabling it to process 4K videos at 30.7 frames per second in real time.

Single Image Haze Removal from Image Enhancement Perspective for Real-Time Vision-Based Systems.

Vision-based systems operating outdoors are significantly affected by weather conditions, notably those related to atmospheric turbidity. Accordingly, haze removal algorithms, actively being researched over the last decade, have come into use as a pre-processing step. Although numerous approaches have existed previously, an efficient method coupled with fast implementation is still in great demand. This paper proposes a single image haze removal algorithm with a corresponding hardware implementation for facilitating real-time processing. Contrary to methods that invert the physical model describing the formation of hazy images, the proposed approach mainly exploits computationally efficient image processing techniques such as detail enhancement, multiple-exposure image fusion, and adaptive tone remapping. Therefore, it possesses low computational complexity while achieving good performance compared to other state-of-the-art methods. Moreover, the low computational cost also brings about a compact hardware implementation capable of handling high-quality videos at an acceptable rate, that is, greater than 25 frames per second, as verified with a Field Programmable Gate Array chip. The software source code and datasets are available online for public use.

Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease.

A 26-year-old male with a history of pre-B cell acute lymphoblastic leukemia and seizures presented with second relapse of acute lymphoblastic leukemia and central nervous system involvement, 19 years after the initial diagnosis. Over the next two months, the patient received six doses of triple intrathecal chemotherapy (cytarabine, methotrexate, and hydrocortisone), three concurrently with continuous blinatumomab in the second month. Approximately 12 days after blinatumomab initiation, he developed central nervous system toxicity manifesting as speech impairment, altered mental status, incontinence, and diffuse weakness. Blinatumomab was discontinued, and he was started on dexamethasone. Within the next couple of months, his neurologic status recovered, and he was able to perform all of his baseline activities without limitation. Unfortunately, the patient eventually expired after further relapse approximately one year later. To our knowledge, this is the first published case report of severe neurotoxicity in a patient who was given blinatumomab concurrently with intrathecal chemotherapy.